Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression Fracture

Inclusion Criteria: * Postmenopausal women over 40 years of age * Compression fracture of the spine confirmed by MRI or bone scan * When the T score of the lumbar spine is less than -1.0 in the bone density test using DXA (Dual energy X ray absorptiometry) * Compression fracture is between 5th thoracic and 5th lumbar vertebra * When a new vertebral fracture occurs in less than 3 parts of the spine * Compression fracture of the spine within 6 weeks after minor trauma * Oswestry Disability Index (ODI) due to vertebral fracture is more than 30% * Back pain due to vertebral fracture has a Visual Analogue Scale (VAS) of 4 or higher. * In case of writing consent for stem cell transplantation therapy Exclusion Criteria: * Those who used osteoporosis treatment (bisphosphonate, selective estrogen receptor modulator, or parathyroid hormone) 6 months before the start of the clinical trial due to osteoporotic vertebral fracture. * In the case of inherited, metabolic, neoplastic, or infectious bone disease other than osteoporosis * Spinal fracture with neurological symptoms * Those who are taking drugs that affect bone metabolism such as steroids. * Those who have undergone spinal fixation surgery on the fracture site prior to the clinical trial * Those who have a history of psychiatry or who are currently undergoing treatment, who have judged that it is difficult to proceed with the clinical trial under the judgment of the researcher * Those who do not understand the purpose …